+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 18 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.

Age: 18Years +All GendersPhase 3
1452 locations
A

Actively Recruiting

Researchers are conducting a prospective, multi-center observational study in China to better understand drug-induced liver injury DILI. The study aims to explore the clinical features, identify the drugs or herbs causing DILI, assess patient outcomes, and discover new serum markers. The goal is to develop and validate a prognostic model incorporating these novel markers to improve prediction of patient prognosis in China. Participants will be grouped into a modeling group to help build a predictive model for DILI outcomes, and a validation group to test the accuracy of this model. The study collects long-term data to establish and verify these prognostic tools. No experimental treatments are given as this is an observational cohort study. During the study, researchers will monitor participants for key outcomes such as death, liver transplantation, and acute liver failure over one year, as well as chronic DILI and recovery over two years. Data will be collected through regular clinical assessments and laboratory tests. This long-term follow-up will help improve understanding of DILI prognosis and validate new serum biomarkers. Participants will be involved over extended periods to ensure comprehensive outcome measurement.

Age: 18Years +All Genders
13 locations
A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
M

Actively Recruiting

This trial investigates the effects of different durations of fasting after esophageal variceal ligation therapy in patients with cirrhosis and portal hypertension. Researchers aim to compare early postoperative oral intake with a 6-hour fasting period against delayed oral intake with fasting periods of 24 or 48 hours. The study evaluates the safety and effectiveness of these approaches in reducing early postoperative rebleeding. Participants are randomly assigned to one of three groups with varying fasting durations after ligation surgery 6 hours, 24 hours, or 48 hours. The 6-hour fasting group begins with a liquid diet during the first day after surgery, progressing to semi-liquid or soft diets by days 4-7, and regular diets starting day 8. The groups fasting 24 or 48 hours receive intravenous fluids during fasting, followed by gradual diet progression similar to the 6-hour group. This study is conducted across multiple centers and uses a quadruple-blind design. During the study, participants will be monitored for early rebleeding events over 6 weeks, with additional assessments of hospital stay length, nutritional status, and non-bleeding adverse events over 4 weeks. Researchers will track diet tolerance and complications through scheduled visits and evaluations. The study runs from June 2026 to June 2027, with careful safety and outcome monitoring to understand the impact of fasting duration on recovery after variceal ligation.

Age: 18Years +All GendersPhase Not Applicable
12 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
C

Actively Recruiting

Researchers are evaluating the long-term effectiveness and safety of drug-coated balloon DCB strategies, including DCB alone or combined with drug-eluting stents DES, compared to DES-only treatment in patients with chronic total occlusion CTO of coronary arteries after successful reopening. This multicenter randomized controlled trial aims to fill the gap in direct comparative data between DCB and DES treatments for CTO, with the goal of optimizing treatment strategies, reducing stent use, lowering complication risks, and improving patient outcomes. Participants will be randomly assigned to either the DCB group, which involves balloon angioplasty with drug coating and possible provisional DES implantation if needed hybrid strategy, or the DES-only group receiving standard drug-eluting stent placement. Both groups receive standard medical therapy including at least 12 months of dual antiplatelet therapy DAPT. The study includes a 9-month primary endpoint assessment and a 36-month follow-up period to monitor long-term outcomes. During the study, patients will undergo angiographic evaluation for late lumen loss at 9 months, assessed by an independent laboratory using quantitative coronary angiography. Clinical events such as target lesion failure, cardiac death, myocardial infarction, and repeat revascularization will be monitored up to 36 months. Patient-reported outcomes like angina status and quality of life, as well as intravascular imaging and safety parameters, will also be collected. Overall participation spans over three years with regular follow-up visits to assess treatment effects and safety.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
18 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of TQB6411 Injection in adults with recurrent or metastatic esophageal cancer who have not responded to prior treatment with PD-1PD-L1 inhibitors combined with platinum-based chemotherapy. This study includes both Phase Ib, focusing on safety and tolerance, and Phase II, which assesses how well the treatment works in this patient group. Participants receive TQB6411 Injection in treatment cycles lasting either 21 or 28 days. TQB6411 is an antibody-drug conjugate targeting specific proteins EGFR and c-Met involved in cancer growth. The treatment is given continuously during the study period to evaluate its effects and safety. During the trial, participants will have regular assessments including tumor measurements, blood tests, and monitoring for side effects over a period of up to 24 months. Researchers will measure outcomes such as recommended dose, adverse events, progression-free survival, response rates, and overall survival. Additional tests will evaluate drug concentration in the blood and immune responses to the treatment. Participants will be closely monitored for safety throughout the study duration.

Age: 18Years - 75YearsAll GendersPhase 1Phase 2
30 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.

Age: 18Years - 80YearsAll GendersPhase 3
41 locations
S

Actively Recruiting

Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.

Age: 40Years - 80YearsAll GendersPhase 3
314 locations
S

Actively Recruiting

Researchers are evaluating the safety of inhaled TQC3721 suspension, a Phosphodiesterase34 inhibitor, in patients with moderate to severe Chronic Obstructive Pulmonary Disease COPD. This phase 3 study aims to observe adverse effects and lung function changes, providing valuable information about the treatment in this patient group. Participants receive TQC3721 suspension via inhalation at a dose of 6mg2ml twice daily. Two groups are studied one group uses the suspension for 24 weeks, and the other for 12 weeks. The study includes an extended observation period for safety in the longer treatment group. During the trial, participants undergo lung function tests measuring the forced expiratory volume in 1 second FEV1, and lab tests to monitor for adverse events and abnormalities. The study tracks COPD exacerbations and other health changes for up to 48 weeks. Participants are monitored regularly to assess treatment safety and lung function over time.

Age: 40Years - 80YearsAll GendersPhase 3
54 locations

1-10 of 18

1